Search

Displaying results 1181 - 1190 of 2674 in total
  1. Target

    Transient receptor potential cation channel subfamily V member 2

    go.drugbank.com/bio_entities/BE0009158
    TargetHumans

    Calcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...

    Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1
  2. Target

    Ankyrin repeat and protein kinase domain-containing protein 1

    go.drugbank.com/bio_entities/BE0009411
    TargetHumans

    Polypeptides: Ankyrin repeat and protein kinase domain-containing protein 1
  3. Target

    Transient receptor potential cation channel subfamily M member 3

    go.drugbank.com/bio_entities/BE0009808
    TransporterHumans

    Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion.

    Polypeptides: Transient receptor potential cation channel subfamily M member 3Synonyms: Long transient receptor potential channel 3
  4. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    It contains purified immunoglobulin G (IgG) antibodies targeting cytomegalovirus (CMV)[FDA label].

  5. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. … Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion.

  6. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse

  7. Drug

    ANZ-100

    go.drugbank.com/drugs/DB05967
    Investigational

  8. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strain...

  9. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). … [A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or

    Categories: Farnesoid X Receptor Agonist, Farnesoid X Receptor Agonists
  10. Drug

    Chlortetracycline

    go.drugbank.com/drugs/DB09093
    ApprovedVet approvedWithdrawn

    Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of...